After two years of market volatility, the Life Science Tools sector is entering a recovery phase.

Strong structural fundamentals are driving the rebound: underlying drug innovation, expanding clinical pipelines, biopharma funding stabilization, and strategic acquirers actively seeking consolidation opportunities.

Demand is slowly coming back, now is the window for private mid-caps to professionalize the equity story ahead of a 2026 – 2028 exit.

The report covers the current state and near-term outlook of each subsector, including the structural drivers behind sustained demand such as the growth of complex biologics, GLP-1 therapies, and expanding clinical pipelines. It also examines how the market is recovering from the cyclical headwinds of 2024-2025, where we see growth accelerating, and what the M&A and deal activity landscape looks like heading into 2026-2028.

For a detailed discussion of our findings, feel free to contact Matthias Holtmeyer or Marcel Deutschmann.

Please click below if you would like to receive a copy of the full report.